TY - JOUR
T1 - A decade's worth of impact
T2 - Dox loaded liposomes in anticancer activity
AU - Ghosh, Puja
AU - Tiwari, Himja
AU - Lakkakula, Jaya
AU - Roy, Arpita
AU - Emran, Talha Bin
AU - Rashid, Summya
AU - Alghamdi, Saad
AU - Rajab, Bodour S.
AU - Almehmadi, Mazen
AU - Allahyani, Mamdouh
AU - Aljuaid, Abdulelah
AU - Alsaiari, Ahad Amer
AU - Sharma, Rohit
AU - Babalghith, Ahmad O.
N1 - Publisher Copyright:
© 2022
PY - 2022/12
Y1 - 2022/12
N2 - Clinically approved therapeutics associated with cancer are limited to mostly chemotherapy, surgery and radiotherapy in spite of the advancements in the biomedical field. Due to the cardiotoxicity and uncountable side effects brought by the prevailing treatment strategies, demands are growing for targeted drug delivery using nanomaterials. For this the most commonly used drug, doxorubicin (DOX) is encapsulated within several type of nanovesicles to observe their anticancer activity. Among them, DOX encapsulated liposomes gained popularity because of their clinical success and lower toxicity. To enhance their efficiency and site specific delivery, attempts are made to modify the liposomes by combining them with peptides, aptamers, antibodies etc to develop pH, thermal, UV-sensitive and electro-magnetic liposomal nanocarriers for controlled drug release. The novel strategies for the treatment of Breast, Lung, Liver, Pancreatic, Prostate, Ovarian, Cervical, Blood, Brain and Colon cancer using modified liposomes encapsulating DOX are illustrated in this review.
AB - Clinically approved therapeutics associated with cancer are limited to mostly chemotherapy, surgery and radiotherapy in spite of the advancements in the biomedical field. Due to the cardiotoxicity and uncountable side effects brought by the prevailing treatment strategies, demands are growing for targeted drug delivery using nanomaterials. For this the most commonly used drug, doxorubicin (DOX) is encapsulated within several type of nanovesicles to observe their anticancer activity. Among them, DOX encapsulated liposomes gained popularity because of their clinical success and lower toxicity. To enhance their efficiency and site specific delivery, attempts are made to modify the liposomes by combining them with peptides, aptamers, antibodies etc to develop pH, thermal, UV-sensitive and electro-magnetic liposomal nanocarriers for controlled drug release. The novel strategies for the treatment of Breast, Lung, Liver, Pancreatic, Prostate, Ovarian, Cervical, Blood, Brain and Colon cancer using modified liposomes encapsulating DOX are illustrated in this review.
KW - Anticancer
KW - Doxorubicin
KW - Drug delivery
KW - Liposomes
KW - Nanomaterial
UR - http://www.scopus.com/inward/record.url?scp=85141272348&partnerID=8YFLogxK
U2 - 10.1016/j.mtadv.2022.100313
DO - 10.1016/j.mtadv.2022.100313
M3 - Article
AN - SCOPUS:85141272348
SN - 2590-0498
VL - 16
JO - Materials Today Advances
JF - Materials Today Advances
M1 - 100313
ER -
